132 results about "Smooth muscle" patented technology

Apparatus and methods for deactivating bronchial nerves and ablating smooth muscle extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer (11) is inserted into the bronchus as, for example, by advancing the distal end of a catheter (10) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits ultrasound so as to heat tissues throughout a relatively large impact volume (13) to a temperature sufficient to inactivate nerve conduction and ablate smooth muscle but insufficient to cause rapid ablation or necrosis of the surrounding tissues. The treatment can be performed without locating or focusing on individual bronchial nerves or smooth muscle.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

The invention discloses a galiaceae-euphorbia tripsacus compound extract as well as a preparation method and vagina repair application thereof. The compound extract is prepared from galiaceae herbs and euphorbia tripsacus according to a scientific ratio through compound enzymolysis pretreatment, gradient ethanol solvent step-by-step extraction and double-resin series purification. According to the preparation method, the dissolution rate of the active components is remarkably increased by utilizing an enzymolysis wall breaking technology, the problem that the purity of the multi-polar components (tannin, flavone and polysaccharide) is difficult to increase and extract at the same time is solved through gradient extraction and series purification, and the purity of the total active components is more than or equal to 60%. The obtained composite extract has multiple effects of astringing and tightening, promoting regeneration of elastic fibers and improving contractility of smooth muscles, and is safe and non-irritant. The invention further discloses targeted sustained-release gel containing the extract, and the targeted sustained-release gel can be used for improving vaginal relaxation and deeply repairing private parts.

The invention discloses a functional coating, an intravascular stent and a preparation method and application of the intravascular stent. The functional coating comprises an endothelialization promoting active substance and an anti-proliferation drug; the endothelialization promoting active substance comprises at least one of polypeptide containing an RGD sequence, polypeptide containing a YIGSR sequence, polypeptide containing an REDV sequence, a beta-polypeptide polymer or a beta-polypeptide-polyester block copolymer. The functional coating disclosed by the invention can be used for surface functional modification of interventional medical devices, can selectively promote adhesion and proliferation of vascular endothelial cells at an implantation part, realizes rapid endothelialization, and can controllably release an anti-proliferation drug to inhibit excessive proliferation of vascular smooth muscle cells, so that the vascular endothelial cells are prevented from being damaged. Therefore, the risks of restenosis and advanced thrombus are effectively reduced.

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The invention provides application of retinoic acid in preparation of a medicine for treating vascular calcification, and belongs to the technical field of medicines. The early warning and treatment effects of retinoic acid on vascular calcification are provided for the first time, a new source is provided for preparing the medicine for early warning and / or treating vascular calcification, and meanwhile the new medicinal value of retinoic acid is explored. Cardiovascular calcification and vascular smooth muscle cell calcification are relieved by supplementing retinoic acid in vivo and in vitro, and the feasibility that retinoic acid can be used as a potential medicine for treating vascular calcification is prompted. The retinoic acid content is in negative correlation with the coronary artery calcification integral of the human body and the calcification severity degree, and it is prompted that the retinoic acid content can serve as an early warning index of cardiovascular calcification and the severity degree.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The invention belongs to the technical field of molecular biology diagnosis and treatment, and relates to application of a reagent for detecting or inhibiting FN1 and a product for diagnosing or preventing and treating vascular restenosis. The expression level of the FN1 in a vascular restenosis sample is remarkably increased, and the FN1 can promote phenotypic transformation of vascular smooth muscle cells (VSMC). Meanwhile, further research proves that the FN1 has better diagnosis efficiency on the diagnosis of the vascular restenosis, and is higher in sensitivity, specificity and accuracy, so that the FN1 can be used for effectively diagnosing the vascular restenosis. In addition, in-vivo experiments prove that VSMC phenotypic transformation can be inhibited and vascular restenosis can be improved by inhibiting FN1 expression. The invention provides a new direction for research and development of vascular restenosis related diagnosis and prevention and treatment products, and has a good clinical application prospect.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The invention belongs to the technical field of artery stents, and particularly relates to a degradable coronary artery stent and a preparation method thereof. Wherein the degradable coronary stent is of a tubular network structure prepared by a main frame and connecting rib components, the main frame is of an open network structure, anchoring points are arranged at nodes, and the connecting rib components are detachably connected and lock the main frame through the anchoring points to form an integral rigid structure, so that the elastic retraction force after a blood vessel is implanted is effectively resisted; the connecting rib component is gradually degraded and loses the locking capacity along with the promotion of vascular repair, the loaded rapamycin is synchronously released, smooth muscle cells with active proliferation are accurately inhibited, the risk of restenosis in the stent is reduced, meanwhile, the activity of the main framework is recovered, the main framework slightly deforms along with vascular pulsation, and vascular intimal injury and inflammatory response are reduced.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

The invention relates to the technical field of biomedical materials. The invention discloses a Schiff base-sulfonated hyaluronic acid light-cured microsphere as well as a preparation method and application thereof. The microspheres are prepared by condensing DL-lysine and paeonol to generate Schiff base, then conjugating the Schiff base with sulfonated hyaluronic acid through a carbodiimide chemical method, and finally molding by adopting a microfluidic technology and carrying out ultraviolet curing. The metal chelation characteristic of Schiff base is combined with the precise structure regulation advantage of the microspheres, and the prepared microspheres show an excellent synergistic effect when applied to the surfaces of implant materials such as degradable magnesium alloy, iron alloy and zinc alloy: the corrosion resistance of a base material can be remarkably improved, an effective protective layer is formed, and the service life of the microspheres is prolonged. Meanwhile, the compound has multiple biological functions of promoting endothelial cell proliferation, inhibiting excessive proliferation of smooth muscle cells and regulating and controlling macrophages to be polarized to anti-inflammatory phenotypes, and has a wide application prospect in the biomedical fields of intravascular stents, bone fixing instruments and the like.

The invention discloses a composite medicine coating for treating pulmonary arterial hypertension, and belongs to the technical field of medical instruments. The coating is composed of an inert protective layer and a composite drug coating, the inert protective layer is a polyamino acid polymer, responds to pH change and is rapidly disintegrated only in the pH environment of a target site, and the loss of the composite drug coating in the delivery process is reduced; the composite drug coating is a composite component containing two or more gene regulatory factors and / or drugs, achieves a synergistic effect through a signal path, cells and a gene level, more efficiently regulates pulmonary artery endothelial cell dysfunction and smooth muscle cell injury, and has precise targeting and irreplaceability.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

The invention relates to the technical field of biomedicine, in particular to application of CCN2 serving as a target spot to preparation of a medicine for diagnosing, preventing and / or treating anti-phospholipid syndrome. The invention provides application of CCN2 serving as a biomarker to diagnosis of APS and other related vasculopathy, application of CCN2 serving as a treatment target to preparation of drugs for preventing and / or treating anti-phospholipid syndromes and an establishment method of an APS related vasculopathy model. According to the invention, it is found for the first time that CCN2 targets in APS blood vessels play a crucial role in promoting proliferation and migration of vascular endothelial cells and vascular smooth muscle cells, a new perspective is provided for knowing cell and molecular mechanisms of vasculopathy, and it is determined that CCN2 can be used as a potential biomarker for diagnosing APS vasculopathy and evaluating disease progression of APS vasculopathy. And potential targets for clinical anti-proliferation treatment.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses a low-voltage nanosecond pulse platform waveform fitting method, and belongs to the technical field of high-frequency pulse control, and the method comprises the steps: obtaining a set voltage value, calculating the optimal pulse width corresponding to a target cell through a transmembrane voltage formula according to the set voltage value, and calculating the optimal pulse width according to a dose and transmembrane potential accumulation model. Calculating the number of equivalent nanosecond pulse sub-pulses capable of replacing the optimal pulse width, calculating the number of pulse strings according to the total dose set by the optimal pulse width and the number of the equivalent nanosecond pulse sub-pulses, fitting nanosecond pulses, and replacing the optimal pulse width, the calculated nanosecond fitting value, the calculated pulse string number and preset parameters are stored in a storage chip of the pulse platform, the pulse platform calls the storage parameters for energy emission, the low-voltage nanosecond platform can be used for achieving the combined effect of a microsecond platform and a high-voltage nanosecond platform, released bubbles are smaller than those of the microsecond platform, the occurrence rate of embolism is reduced, and the service life of the microsecond platform is prolonged. The released voltage is lower than that of traditional nanoseconds, and the problems of blood fusion and smooth muscle and nerve damage are reduced.

The invention belongs to the field of biological medicine, and particularly relates to application of a compound in preparation of a medicine for preventing and treating aortic dissection, the compound is nobiletin, the chemical name of the compound is 3 ', 4', 5, 6, 7, 8-hexamethoxyflavone, and the CAS number is 478-01-3. The invention also correspondingly provides a pharmaceutical composition. The death rate of aortic dissection is high, treatment depends on surgical treatment, and the death rate is extremely high. At present, an effective medicine for preventing and treating the aortic dissection is lacked clinically, the nobiletin is screened and determined to be used as the medicine for preventing and treating the aortic dissection, the molecular mechanism of the nobiletin is clear that the nobiletin targets ferroptosis related protein SLC7A11 to improve ferroptosis of vascular smooth muscle cells, namely VSMC, and a new target spot is provided for treatment of the aortic dissection.

The utility model provides a cutting woven covered stent, which relates to the technical field of medical instruments, and comprises a cutting skeleton, a woven mesh and an ePTFE membrane, the cutting skeleton is designed by combining an open loop and a closed loop, and the two ends of the stent have a good anchoring effect in vivo; and the middle part is of an open-loop structure, and through the support of the woven mesh, the whole body has good support performance and also has flexibility. The stent composed of the cutting framework, the woven mesh and the ePTFE membrane is arranged, the cutting framework is designed by combining an open loop and a closed loop, and the two ends of the stent have a good anchoring effect in the body; and the middle part is of an open-loop structure, and through the support of the woven mesh, the whole body not only has good support performance, but also has flexibility. The outer layer is coated with the ePTFE membrane, so that the coverage area on plaques is larger, the probability that the plaques fall off from stent meshes can be effectively reduced, and micro-embolism after the plaques fall off is prevented. The ePTFE membranes on the inner layer and the outer layer are dip-coated with the drug-loaded coatings, proliferation of vascular smooth muscles is inhibited, and intravascular restenosis is prevented.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

The implantable device disclosed by the invention is provided with at least one corrodible zinc-containing part, and the zinc content in the at least one zinc-containing part is within the range of [30,000, 3,000, 3,000]. The zinc content range of at least one of the zinc-containing parts is [50, 70] wt.%, the zinc in the zinc-containing parts is an amorphous structure, or the zinc content range of at least one of the zinc-containing parts is [50, 70] wt.%, and the microstructure of the zinc in the zinc-containing parts is selected from at least one of an amorphous structure, a non-equiaxed structure, an ultra-fine structure or an equiaxed structure with the grain size range of 7-14 grades, or the microstructure of the zinc in the zinc-containing parts is selected from at least one of an amorphous structure, a non-equiaxed structure, an ultra-fine structure or an equiaxed structure with the grain size range of 7-14 grades. The zinc content range of at least one zinc-containing part is (70, 100) wt.%, and the microstructure of zinc in the zinc-containing part is selected from at least one of a non-equiaxed crystal structure, an ultra-fine crystal structure or an equiaxed crystal structure with the grain size range of 7-14 grades. After the implantable instrument is implanted into a body, a zinc corrosion product is generated, and the concentration of the zinc corrosion product in the surrounding tissue of the zinc-containing part of the implantable instrument can inhibit smooth muscle cell proliferation and cannot cause normal tissue cell necrosis.

The invention provides application of a mucolipoprotein transient receptor potential channel 1 as a target spot in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to the technical field of biological medicine manufacturing. The invention relates to application of a mucolipoprotein transient receptor potential channel 1 (TRRP Mucipin1, TRPML1) as a target spot in preparation, development or screening of a medicine for treating pulmonary hypertension (PH), in particular to application of the medicine in preparation, development or screening of the medicine for treating the PH. The invention also provides application of a reagent 1 for up-regulating smooth muscle cell Mcoln1 gene and / or smooth muscle cell TRPML1 protein expression or a reagent 2 for improving smooth muscle cell TRPML1 protein activity in preparation of drugs for treating PH. Experiments show that the over-expressed TRPML1 in the smooth muscle affects the PH pulmonary vascular remodeling process and PH generation and development through autophagy regulation and control, and the purpose of PH treatment is achieved.

The invention relates to the technical field of molecular biology and medicine, and particularly discloses application of WWP1 in preparation of a medicine for preventing and / or treating aortic dissection, and relates to application of WWP1 in prevention and treatment of aortic dissection. Molecular biology experiment detection of the expression level of the WWP1 in aortic dissection aortic tissue and the expression level of smooth muscle cell contraction and secretion phenotype marker genes proves that the expression level of the WWP1 in an aortic dissection aortic tissue sample is obviously higher than that of a control aortic tissue; and overexpression of the WWP1 in an animal model significantly reduces the morbidity of the aortic dissection and improves the contraction phenotype of the aortic smooth muscle, i.e., the protectiveness of the WWP1 in the morbidity process of the aortic dissection is improved. Based on the research result, the WWP1 can be used as a drug target for screening, preventing and treating the aortic dissection.

The invention belongs to the technical field of biological medicines, and discloses a deep sea steroid compound, a preparation method thereof and application of the deep sea steroid compound in preparation of medicines for preventing or treating renal fibrosis. The steroid compound is a class of highly oxidized and modified ergoketone compounds, and in some embodiments, the compound has an unusual malonyl substitution at the C-12 position of an ergoketone skeleton. The steroidal compound disclosed by the invention can achieve the effect of inhibiting renal fibrosis by regulating and controlling expression down-regulation of key fibrosis markers, namely alpha-smooth muscle actin (alpha-SMA) and I-type collagen (COL1A1), and has an inhibiting effect on proliferation of TGF-beta1-induced mouse renal fibroblasts; therefore, the compound has a great application prospect in preparation of drugs for preventing or treating renal fibrosis.